Therapeutics in the neurorehabilitation of Parkinson's disease

被引：0

作者：

Colcher, A ^{[1
]}

Stern, MB ^{[1
]}

机构：

[1] Penn State Univ, Penn Neurol Inst, Parkinsons Dis & Movement Disorders Ctr, Philadelphia, PA 19107 USA

来源：

NEUROREHABILITATION AND NEURAL REPAIR | 1999年 / 13卷 / 04期

关键词：

D O I：

10.1177/154596839901300402

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Parkinson's disease (PD) affects 1 percent of the population over the age of 65. The number of people with this disorder is steadily rising. Therapy for PD remains primarily pharmacologic, with medications that target the depleted dopaminergic system being the mainstay of therapy. Surgical therapies, both ablative and stimulatory, are increasingly being used for patients with more advanced disease and/or complications of drug therapy. Experimental therapies aimed at restoring dopaminergic function and protecting dopaminergic cells are being studied. Alternate neurotransmitter systems are being evaluated as potential targets for therapy. Complete treatment of patients with PD utilizes education, physical therapy, support groups, and medication. When a comprehensive approach is used, PD is treatable and manageable.

引用

页码：205 / 218

页数：14

共 84 条

[1]

[Anonymous], 1996, Ann Neurol, V39, P37

[2]

[Anonymous], MOVEMENT DISORDERS

[3] Catechol-O-methyltransferase inhibition with tolcapone reduces the ''wearing off'' phenomenon and levodopa requirements in fluctuating parkinsonian patients [J].

Baas, H ;

Beiske, AG ;

Ghika, J ;

Jackson, M ;

Oertel, WH ;

Poewe, W ;

Ransmayr, G ;

Auff, E ;

Volc, D ;

Dupont, E ;

Mikkelsen, B ;

Wermuth, L ;

WommPetersen, J ;

Benecke, R ;

Eichhom, T ;

Kolbe, H ;

Oertel, W ;

Schimrigk, K ;

Olsson, JE ;

Palhagen, S ;

Burgunder, JM ;

Ghika, A ;

Regli, F ;

Steck, A ;

Medcalf, P .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (04) :421-428

[4] Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study [J].

Baron, MS ;

Vitek, JL ;

Bakay, RAE ;

Green, J ;

Kaneoke, Y ;

Hashimoto, T ;

Turner, RS ;

Woodard, JL ;

Cole, SA ;

McDonald, WM ;

Delong, MR .

ANNALS OF NEUROLOGY, 1996, 40 (03) :355-366

[5]

BASMA AN, 1995, J NEUROCHEM, V64, P825

[6] Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: A comparison with L-Dopa treatment [J].

Benazzouz, A ;

Boraud, T ;

Feger, J ;

Burbaud, P ;

Bioulac, B ;

Gross, C .

MOVEMENT DISORDERS, 1996, 11 (06) :627-632

[7]

BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5

[8] Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].

Block, G ;

Liss, C ;

Reines, S ;

Irr, J ;

Nibbelink, D ;

Aarli, J ;

Aguilar, M ;

Ahrens, S ;

Bakheit, A ;

Baumel, B ;

Bertoni, J ;

Capildeo, R ;

CastroCaldas, A ;

Deza, L ;

Donaldson, I ;

Franck, G ;

Fusillo, J ;

Gauthier, S ;

Gershanik, O ;

Granerus, AK ;

Hauser, RA ;

Hennessey, K ;

Hutton, JT ;

Joffe, R ;

Koller, W ;

Last, B ;

LeWitt, P ;

Mamoli, B ;

Manyam, B ;

Mark, M ;

Nakano, K ;

Nausieda, P ;

Otero, E ;

Paulson, G ;

Pinter, M ;

Reich, S ;

Rodnitzky, R ;

Sage, J ;

Sampaio, C ;

Smith, B ;

Teravainen, H ;

Tetrud, J ;

Tolosa, E ;

Ulm, G ;

Valesco, F .

EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27

[9]

BUTZER JF, 1975, NEUROLOGY, V25, P603

[10]

Cassarino DS, 1998, J NEUROCHEM, V71, P295

← 1 2 3 4 5 6 7 8 9 →